1. Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet Digit Health. 2020;2(6):e286-e287. [DOI:10.1016/S2589-7500(20)30086-8] [PMID]

2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. [DOI:10.1016/S0140-6736(20)30566-3]

3. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R. World Health Organization Solidarity Vaccines Trial Expert Group. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet. 2020;396(10253):741-743. [DOI:10.1016/S0140-6736(20)31821-3] [PMID]

4. Adedokun KA, Kamorudeen RT, Bello IO. Authorization of the first COVID-19 emergency vaccines: The matters arising. EXCLI J. 2021 Mar 15;20:655-660. doi: 10.17179/excli2021-3384.

5. Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, Neels P. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022 May;21(5):609-619. doi: 10.1080/14760584.2022.2042257. [DOI:10.1080/14760584.2022.2042257] [PMID] []

6. Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science. 2020;370(6518):763-765. [DOI:10.1126/science.abe5938] [PMID]

7. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-632. [DOI:10.1038/s41577-020-00434-6] [PMID] []

8. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642-643. [DOI:10.1016/S0140-6736(21)00191-4] [PMID]

9. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. [DOI:10.1016/S0140-6736(21)00234-8] [PMID]

10. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID‑19 vaccine safety. Int J Mol Med. 2020;46(5):1599-1602. [DOI:10.3892/ijmm.2020.4733] [PMID] []

11. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. [DOI:10.1016/S0140-6736(20)31866-3]

12. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-488. [DOI:10.1016/S0140-6736(20)31605-6] [PMID]

13. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017;13(3):613-620. [DOI:10.1080/21645515.2016.1238535] []

14. Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021;595(7867):339-340. [DOI:10.1038/d41586-021-01813-2]